CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis

F Sellebjerg; C Ross; Nils Koch-Henriksen; P Soelberg Sørensen; J L Frederiksen; K Bendtzen; Torben Lykke Sørensen

CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis

F Sellebjerg, C Ross, Nils Koch-Henriksen, P Soelberg Sørensen, J L Frederiksen, K Bendtzen, Torben Lykke Sørensen

Department of Clinical Medicine

13 Citations (Scopus)

Abstract

Biomarkers that allow the identification of patients with multiple sclerosis (MS) with an insufficient response to immunomodulatory treatment would be desirable, as currently available treatments are only incompletely efficacious. Previous studies have shown that the expression of CD25, CD26 and CCR5 on T cells is altered in patients with active MS. We studied the expression of these molecules by flow cytometry in patients followed for six months during immunomodulatory treatment. In interferon (IFN)-beta-treated patients, we found that the hazard ratio for developing an attack was 28 in patients with CD26 + CD4 + T cell counts above median, and this risk was independent of the risk conferred by neutralizing anti-IFN-beta antibodies. CD26 + CD4 + T cell counts may identify patients with MS at increased risk of attack during treatment with IFN-beta.

Original language	English
Journal	Multiple Sclerosis
Volume	11
Issue number	6
Pages (from-to)	641-5
Number of pages	5
ISSN	1352-4585
Publication status	Published - 1 Dec 2005

Cite this

@article{67d6e02e89434169a4d51325e9a12479,

title = "CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis",

abstract = "Biomarkers that allow the identification of patients with multiple sclerosis (MS) with an insufficient response to immunomodulatory treatment would be desirable, as currently available treatments are only incompletely efficacious. Previous studies have shown that the expression of CD25, CD26 and CCR5 on T cells is altered in patients with active MS. We studied the expression of these molecules by flow cytometry in patients followed for six months during immunomodulatory treatment. In interferon (IFN)-beta-treated patients, we found that the hazard ratio for developing an attack was 28 in patients with CD26 + CD4 + T cell counts above median, and this risk was independent of the risk conferred by neutralizing anti-IFN-beta antibodies. CD26 + CD4 + T cell counts may identify patients with MS at increased risk of attack during treatment with IFN-beta.",

author = "F Sellebjerg and C Ross and Nils Koch-Henriksen and S{\o}rensen, {P Soelberg} and Frederiksen, {J L} and K Bendtzen and S{\o}rensen, {Torben Lykke}",

year = "2005",

month = dec,

day = "1",

language = "English",

volume = "11",

pages = "641--5",

journal = "Multiple Sclerosis",

issn = "1352-4585",

publisher = "SAGE Publications",

number = "6",

}

TY - JOUR

T1 - CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis

AU - Sellebjerg, F

AU - Ross, C

AU - Koch-Henriksen, Nils

AU - Sørensen, P Soelberg

AU - Frederiksen, J L

AU - Bendtzen, K

AU - Sørensen, Torben Lykke

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Biomarkers that allow the identification of patients with multiple sclerosis (MS) with an insufficient response to immunomodulatory treatment would be desirable, as currently available treatments are only incompletely efficacious. Previous studies have shown that the expression of CD25, CD26 and CCR5 on T cells is altered in patients with active MS. We studied the expression of these molecules by flow cytometry in patients followed for six months during immunomodulatory treatment. In interferon (IFN)-beta-treated patients, we found that the hazard ratio for developing an attack was 28 in patients with CD26 + CD4 + T cell counts above median, and this risk was independent of the risk conferred by neutralizing anti-IFN-beta antibodies. CD26 + CD4 + T cell counts may identify patients with MS at increased risk of attack during treatment with IFN-beta.

AB - Biomarkers that allow the identification of patients with multiple sclerosis (MS) with an insufficient response to immunomodulatory treatment would be desirable, as currently available treatments are only incompletely efficacious. Previous studies have shown that the expression of CD25, CD26 and CCR5 on T cells is altered in patients with active MS. We studied the expression of these molecules by flow cytometry in patients followed for six months during immunomodulatory treatment. In interferon (IFN)-beta-treated patients, we found that the hazard ratio for developing an attack was 28 in patients with CD26 + CD4 + T cell counts above median, and this risk was independent of the risk conferred by neutralizing anti-IFN-beta antibodies. CD26 + CD4 + T cell counts may identify patients with MS at increased risk of attack during treatment with IFN-beta.

M3 - Journal article

SN - 1352-4585

VL - 11

SP - 641

EP - 645

JO - Multiple Sclerosis

JF - Multiple Sclerosis

IS - 6

ER -

CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis

Abstract

Fingerprint

Cite this